We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Gene Expression in Core Needle Biopsy Diagnoses Breast Cancer

By HospiMedica staff writers
Posted on 28 Aug 2006
The gene-expression profile detected in a core needle biopsy of a breast tumor is representative of gene expression in the whole tumor and therefore a reliable diagnostic for breast cancer, according to a new study.

The study, published in the August 2006 edition of the journal Breast Cancer Research, confirms the reliability of core needle biopsy as a tool in breast-cancer diagnosis and prognosis. More...
The study also shows that the gene expression profile of a core needle biopsy might be more accurate than the profile of a surgical sample taken from the same tumor after the biopsy was carried out. According to the study results, the biopsy procedure triggers the expression of genes involved in wound healing as well as tumor invasion and metastasis, thus modifying the gene expression profile of subsequent surgical samples.

Dr. Rosanna Zanetti-Dällenbach, from the Women's University Hospital (Basel, Switzerland), and colleagues analyzed the gene expression profile of core needle biopsies taken from 22 women diagnosed with breast cancer. For each woman, they compared the biopsy expression profile with the expression profile of a surgical sample taken from the tumor subsequent to the core needle biopsy. They quantified the expression of 60 genes known to be involved in breast tumor development using reverse transcription polymerase chain reaction (RT-PCR). Dr. Zanetti-Dällenbach and colleagues also analyzed the gene expression profiles of surgical samples taken from breast tumors of 317 patients who did not undergo a core needle biopsy.

The results of the study showed that the gene expression levels of the core biopsy and the surgical sample are identical for most women. However, the expression of four specific genes was significantly increased in the surgical samples compared to the core needle biopsies. In the group of women who did not get a core needle biopsy, however, the expression of these four genes was not increased. These four genes are involved in inflammation and wound repair as well as tumor invasion and metastasis. The authors conclude that their expression must therefore be modified by the core needle biopsy procedure itself and they warn that care should be taken when interpreting the gene expression profile of a surgical sample carried out following a core biopsy.



Related Links:
Women's U. Hospital

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.